AIM: Chronic kidney disease (CKD) is a progressive disease which is becoming a major public health issue due to its high rate of premature death, poor quality of life and expensive end-stage treatment (dialysis or transplantation). The burden of this chronic condition in a community setting was examined. METHODS: Data were obtained from 369,098 Tasmanian adults (aged >or=18 years) and included 1,640,687 measurements of creatinine taken between 1995 and 2007. In 2007 alone, testing comprised 25.5% of the state's adult population. A modelled estimate of CKD prevalence was developed. RESULTS: For those at risk of CKD (aged >50 years), 50.6%, 70.2% and 82% had a measured creatinine (and reported estimated glomerular filtration rate (eGFR)) during the last 1, 2 and 3 years respectively. However, only 9.4% of people with eGFR of less than 60 mL/min per 1.73 m(2) had albuminuria formally measured. Estimated prevalence of stage III or greater CKD (eGFR <60 mL/min per 1.73 m(2)) was at least 11.4% of women and 8.6% of men during 2007. Detection of low eGFR increased significantly over the last 13 years. There was a large geographic variation throughout Tasmania and high relative mortality with lower eGFR. There is a broad gap between the number of people with eGFR of less than 15 mL/min per 1.73 m(2) (stage V CKD) and those receiving dialysis treatment. CONCLUSION: The number of people identified with low eGFR has increased significantly since 1995 with a large geographic variation. Despite this, testing for kidney disease (by measuring serum creatinine and albuminuria) in people at risk is still suboptimal.
AIM: Chronic kidney disease (CKD) is a progressive disease which is becoming a major public health issue due to its high rate of premature death, poor quality of life and expensive end-stage treatment (dialysis or transplantation). The burden of this chronic condition in a community setting was examined. METHODS: Data were obtained from 369,098 Tasmanian adults (aged >or=18 years) and included 1,640,687 measurements of creatinine taken between 1995 and 2007. In 2007 alone, testing comprised 25.5% of the state's adult population. A modelled estimate of CKD prevalence was developed. RESULTS: For those at risk of CKD (aged >50 years), 50.6%, 70.2% and 82% had a measured creatinine (and reported estimated glomerular filtration rate (eGFR)) during the last 1, 2 and 3 years respectively. However, only 9.4% of people with eGFR of less than 60 mL/min per 1.73 m(2) had albuminuria formally measured. Estimated prevalence of stage III or greater CKD (eGFR <60 mL/min per 1.73 m(2)) was at least 11.4% of women and 8.6% of men during 2007. Detection of low eGFR increased significantly over the last 13 years. There was a large geographic variation throughout Tasmania and high relative mortality with lower eGFR. There is a broad gap between the number of people with eGFR of less than 15 mL/min per 1.73 m(2) (stage V CKD) and those receiving dialysis treatment. CONCLUSION: The number of people identified with low eGFR has increased significantly since 1995 with a large geographic variation. Despite this, testing for kidney disease (by measuring serum creatinine and albuminuria) in people at risk is still suboptimal.
Authors: Pankti A Gheewala; Gregory M Peterson; Colin M Curtain; Prasad S Nishtala; Paul J Hannan; Ronald L Castelino Journal: Drugs Aging Date: 2014-11 Impact factor: 3.923
Authors: Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Luke Bereznicki; Matthew D Jose; Ronald L Castelino Journal: Int J Clin Pharm Date: 2016-06-21
Authors: Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs Journal: PLoS One Date: 2016-07-06 Impact factor: 3.240
Authors: Timothy Saunder; Alex Kitsos; Jan Radford; Kim Jose; Charlotte McKercher; Rajesh Raj; Nadine Wiggins; Brian Stokes; Matthew D Jose Journal: JMIR Res Protoc Date: 2020-09-17
Authors: Charlotte M McKercher; Alison J Venn; Leigh Blizzard; Mark R Nelson; Andrew J Palmer; Michael A Ashby; Jennifer L Scott; Matthew D Jose Journal: BMC Nephrol Date: 2013-04-12 Impact factor: 2.388
Authors: Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino Journal: Prev Chronic Dis Date: 2018-06-14 Impact factor: 2.830